Freneslerbart

Phase 3

Regeneron

Freneslerbart is one of 16 therapeutic programs targeting Allergic Conjunctivitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Allergic ConjunctivitisRecruiting

Allergic ConjunctivitisPhase 3

Recruiting

Competition

Competitive Landscape

17 competitors in Allergic Conjunctivitis

#DrugCompanyPhaseTrials

Neoral

Novartis

Approved

—2

Flovent

PParatek Pharmaceuticals Inc

Approved

1 3

Claritin

PPerrigo Company

Approved

1 4

Flovent

PParatek Pharmaceuticals Inc

Approved

1 5

Lotemax

PPharmos

Approved

1 6

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—7

Prograf

VVeloxis Pharmaceuticals

Zyrtec

Clarinex

Tobrex

VViatris Specialty LLC

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Recruiting

Allergic Conjunctivitis

NCT07675811

Clinical

Trials by Indication[1]

Allergic Conjunctivitis1 trial

A Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Participants With Allergic Conjunctivitis Due to Cat Allergy

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT07675811·570 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Freneslerbart. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Freneslerbart. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Regeneron

Freneslerbart

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Allergic Conjunctivitis1 trial

References

Drug Info

Quick Facts

Related News